Post Profile

Techdirt has written a number of stories about how Big Pharma is never content with the patent bargain -- that, in return for a time-limited, government-enforced intellectual monopoly, products will afterwards enter the public domain. Instead, companies have come up with various schemes to extend the life of that monopoly -- and thus to cheat the public of the low-cost generic versions of the drug in question that should have appeared.read more

share

Related Posts

We've been writing about the crazy world of pay for delay agreements by big pharmaceutical companies for years now. The short version of it is that big pharmaceutical companies pay off small generic pharma companies to prevent them ...

For many years now, we've been talking about the problematic practice of "pay for delay" in the pharma industry. This involved patent holders paying generic pharmaceutical makers some amount of money to not enter the market in order...

The last time Techdirt wrote about "pay for delay" deals, whereby a big pharma company essentially buys off manufacturers of generics so that the former can continue to enjoy monopoly pricing long after its patents have expired, thi...

For some time now, Techdirt has been following the "pay for delay" scandal, whereby a big pharma company buys off manufacturers of generics so that the former can continue to enjoy monopoly pricing long after its patents have expire...

When Techdirt has written about seeds in the past, it tended to be in the context of patents, and how Big Agribusiness is trying to use multiple layers of intellectual monopolies to prevent patented seeds from entering the public do...